Patents by Inventor Franklin Gerardus Grosveld

Franklin Gerardus Grosveld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11877565
    Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: January 23, 2024
    Assignee: ERASMUS UNIVERSITY MEDICAL CENTER
    Inventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Marinus Johannes Van Haperen
  • Publication number: 20220275059
    Abstract: The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such asthe spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-Swith high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and/or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection.
    Type: Application
    Filed: February 20, 2020
    Publication date: September 1, 2022
    Inventors: Franklin Gerardus GROSVELD, Marinus Johannes VAN HAPEREN, Dubravka DRABEK, Berend Jan BOSCH, Ivy WIDJAJA, Chunyan WANG, Brenda VAN DIEREN, Wentao LI, Frank J.M. VAN KUPPEVELD, Bart L. HAAGMANS, Nisreen M.A. OKBA
  • Publication number: 20220017606
    Abstract: The invention relates to antibodies and antigen-binding fragments thereof that recognize SARS-Cov-2 spike proteins (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and/or inhibit SARS-Cov-2 infection of human cells. in some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection, In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).
    Type: Application
    Filed: July 20, 2021
    Publication date: January 20, 2022
    Inventors: Franklin Gerardus Grosveld, Dubravka Drabek, Rien Van Haperen, Berend Jan Bosch, Juliette Fedry, Daniel L. Hurdiss, Thijs Kuiken, Batholomeus Leonardus Haagmans, Barry Hubertus Gerardus Rockx
  • Publication number: 20210340225
    Abstract: The invention relates to antibodies and antigen-binding fragments thereof that recognize SARS-Cov-2 spike proteins (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and/or inhibit SARS-Cov-2 infection of human cells. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection. In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).
    Type: Application
    Filed: March 5, 2021
    Publication date: November 4, 2021
    Inventors: Franklin Gerardus Grosveld, Dubravka Drabek, Rien van Haperen, Berend Jan Bosch, Juliette Fedry, Daniel L. Hurdiss, Thijs Kuiken, Batholomeus Leonardus Haagmans, Barry Hubertus Gerardus Rockx
  • Patent number: 10993420
    Abstract: A transgenic non-human mammal containing a heterologous heavy chain gene locus that is capable of producing soluble heavy chain only antibodies and antigen-binding fragments thereof following immunization.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 4, 2021
    Assignee: ERASMUS UNIVERSITY MEDICAL CENTER
    Inventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens
  • Patent number: 10906970
    Abstract: The present invention relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: February 2, 2021
    Assignee: Erasmus University Medical Centre
    Inventors: Franklin Gerardus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
  • Publication number: 20200267951
    Abstract: The present invention relates to a method for the generation of VH heavy chain-only antibodies in a transgenic non-human mammal. In particular, the present invention relates to a method for the production of a VH heavy chain-only antibody in a transgenic non-human mammal comprising the step of expressing more than one heterologous VH heavy chain locus in that mammal.
    Type: Application
    Filed: April 15, 2020
    Publication date: August 27, 2020
    Inventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Roger Kingdon Craig
  • Patent number: 10638735
    Abstract: The present invention relates to a method for the generation of VH heavy chain-only antibodies in a transgenic non-human mammal. In particular, the present invention relates to a method for the production of a VH heavy chain-only antibody in a transgenic non-human mammal comprising the step of expressing more than one heterologous VH heavy chain locus in that mammal.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: May 5, 2020
    Assignee: Erasmus University Medical Center
    Inventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Roger Kingdon Craig
  • Publication number: 20180244765
    Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.
    Type: Application
    Filed: April 16, 2018
    Publication date: August 30, 2018
    Applicant: ERASMUS UNIVERSITY MEDICAL CENTRE ROTTERDAM
    Inventors: Franklin Gerardus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
  • Patent number: 9980470
    Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 29, 2018
    Assignee: Erasmus University Medical Center
    Inventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Marinus Johannes Van Haperen, Roger Kingdon Craig, Ernie De Boer
  • Publication number: 20160295843
    Abstract: The present invention relates to a method for the generation of VH heavy chain-only antibodies in a transgenic non-human mammal. In particular, the present invention relates to a method for the production of a VH heavy chain-only antibody in a transgenic non-human mammal comprising the step of expressing more than one heterologous VH heavy chain locus in that mammal.
    Type: Application
    Filed: December 8, 2015
    Publication date: October 13, 2016
    Inventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Roger Kingdon Craig
  • Publication number: 20160295842
    Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.
    Type: Application
    Filed: July 23, 2015
    Publication date: October 13, 2016
    Applicant: Erasmus University Medical Center
    Inventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Marinus Johannes Van Haperen
  • Patent number: 9365655
    Abstract: The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework ?-pleated sheet leading to increased net hydrophobicity within FR1 and increased number of charged amino acids present in FR3. Also provided are VH domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 14, 2016
    Assignee: Erasmus University Medical Center
    Inventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Tao Chen, Ernie De Boer
  • Patent number: 9353179
    Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 31, 2016
    Assignee: Erasmus University Medical Centre
    Inventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
  • Patent number: 9346877
    Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 24, 2016
    Assignee: Erasmus University Medical Centre
    Inventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
  • Patent number: 9131669
    Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: September 15, 2015
    Assignee: ERASMUS UNIVERSITY MEDICAL CENTER
    Inventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Marinus Johannes Van Haperen
  • Patent number: 8921522
    Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: December 30, 2014
    Assignee: Erasmus University Medical Centre
    Inventors: Franklin Gerardus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
  • Publication number: 20140356908
    Abstract: A transgenic non-human mammal containing a heterologous heavy chain gene locus that is capable of producing soluble heavy chain only antibodies and antigen-binding fragments thereof following immunization.
    Type: Application
    Filed: March 14, 2014
    Publication date: December 4, 2014
    Applicant: ERASMUS UNIVERSITY MEDICAL CENTER
    Inventors: FRANKLIN GERARDUS GROSVELD, RICHARD WILHELM JANSSENS
  • Publication number: 20140356907
    Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.
    Type: Application
    Filed: March 14, 2014
    Publication date: December 4, 2014
    Applicant: ERASMUS UNIVERSITY MEDICAL CENTER
    Inventors: FRANKLIN GERARDUS GROSVELD, RICHARD WILHELM JANSSENS, MARINUS JOHANNES VAN HAPEREN, ROGER KINGDON CRAIG, ERNIE DE BOER
  • Patent number: 8883150
    Abstract: The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework ?-pleated sheet leading to increased net hydrophobicity within FR1 and increased number of charged amino acids present in FR3. Also provided are VH domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: November 11, 2014
    Assignee: Erasmus University Medical Center
    Inventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Tao Chen, Ernie De Boer